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Abstract
A major target of the HPV E6 oncoprotein is the human Discs Large (hDlg) tumour suppressor, although how this interaction
contributes to HPV-induced malignancy is still unclear. Using a proteomic approach we show that a strong interacting
partner of hDlg is the RhoG-specific guanine nucleotide exchange factor SGEF. The interaction between hDlg1 and SGEF
involves both PDZ and SH3 domain recognition, and directly contributes to the regulation of SGEF’s cellular localization and
activity. Consistent with this, hDlg is a strong enhancer of RhoG activity, which occurs in an SGEF-dependent manner. We
also show that HPV-18 E6 can interact indirectly with SGEF in a manner that is dependent upon the presence of hDlg and
PDZ binding capacity. In HPV transformed cells, E6 maintains a high level of RhoG activity, and this is dependent upon the
presence of hDlg and SGEF, which are found in complex with E6. Furthermore, we show that E6, hDlg and SGEF each
directly contributes to the invasive capacity of HPV-16 and HPV-18 transformed tumour cells. These studies demonstrate
that hDlg has a distinct oncogenic function in the context of HPV induced malignancy, one of the outcomes of which is
increased RhoG activity and increased invasive capacity.
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Introduction
Human Papillomaviruses (HPVs) are the causative agents of
cervical cancer, the second major cause of cancer-related death in
women worldwide [1,2]. This is brought about by the combined
action of two viral oncoproteins, E6 and E7, which subvert cellular
regulatory pathways controlling cell cycle and cell survival [3,4,5].
Whilst over 100 different HPV types have been identified, only a
small subset have been defined as causative agents for the
development of cervical cancer, and these types are collectively
termed high risk. Amongst these, the most prevalent are HPV-16
and HPV-18, which account for approximately 80% of the cervical
cancer burden [6,7]. Critical cellular targets of the viral oncopro-
teins include p53 and the pRb family of tumour suppressors, which
aresubject toproteasome-mediated degradation[8,9,10].However,
other activities of both E6 and E7 are also required for their full
transforming potential [11,12]. A particularly intriguing class of
substrates for the high risk HPV E6 oncoproteins are cellular
proteins that contain PDZ (PSD95/Dlg/ZO-1) domains, since the
capacity to interact with these cellular proteins is only found
amongst thoseE6 proteins derived from the high risk virus types. To
date, over 10 such PDZ domain-containing targets of E6 have been
identified, and they have been implicated in processes ranging from
control of cell polarity, cell-cell attachment and regulation of diverse
cell signaling pathways [13].
The first PDZ domain-containing target of HPV-16 and HPV-18
E6 to be described was the human homologue of the Drosophila
tumour suppressor protein Discs Large (hDlg) [14,15], which was
shown to be a target for E6-mediated degradation [16]. hDlg is a
member of the membrane-associated guanylate kinase (MAGUK)
family of scaffolding proteins, being found at adherens junctions in
epithelial cells and synaptic junctions in neurons, where it is required
for the correct formation of both types of cell junctions [17–19]. At
these sitesitis believed to actasa scaffoldthat functions byclustering
ion channels [20,21], mediating trafficking of cell surface receptors
[22] and organizing signal transduction pathways through interac-
tion with several proteins such as the actin-associated proteins of the
protein 4.1/ERM (Ezrin, Radixin, Moesin) superfamily [23–24,25–
26], calcium dependent Calmodulin [27], vinexin, b-catenin [28],
and Net1, a RhoA specific GEF [29].
Numerous studies in Drosophila have also shown that mutations
in DLG result in defects in cell polarity and tissue organization,
ultimately resulting in tissue overgrowth and a malignant-like
phenotype [17–19,30], indicating a possible tumour suppressor
function in mammalian cells [31]. Although hDlg has been
implicated directly in the regulation of cell polarity and cell-cell
attachment in mammalian cells [32], its role as a tumour
suppressor is still unclear. Compelling indirect evidence comes
from studies showing that it is also a target for other viral
oncoproteins, including the Adenovirus 9 E4ORF1 and the
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expression in different human tumours, including cervical, colon
and breast cancers, indicates a frequent loss of protein expression
during the later stages of malignancy, which is also consistent with
a tumour suppressor function [35,36]. However, there are also
reports that certain isoforms of hDlg, when subverted by
Adenoviral oncoproteins, may actually possess oncogenic activity
[33]. Furthermore, although hDlg expression is lost during the
later stages of cervical cancer progression, in many high-grade
lesions and cervical tumour-derived cell lines there are still very
high levels of Dlg expression, albeit often mislocalised [35].
The molecular basis underlying hDlg function in tumourigen-
esis is still largely obscure and its role, if any, in the development of
HPV-induced malignancy is still unclear. hDlg is subject to
different post- translational modifications, including being a
substrate for ERK5, CDK1, and CDK2, with the latter being
implicated in its ability to contribute to the control of cell cycle
[37,38]. In addition, hDlg is also phosphorylated by the MAPKs,
p38c and JNK, which control hDlg subcellular distribution and
susceptibility to E6 targeting [39,40]. Thus, whilst hDlg is a
substrate for E6 induced degradation, it is also clear that only
certain cellular pools of the protein are degraded, and significant
levels of hDlg can still be detected in HPV positive tumour cells
[41,40,38].
As a means of better understanding the role of hDlg in HPV-
induced malignancy, we have performed a proteomic analysis to
identify hDlg-interacting partners. We now show that a specific
RhoG guanine nucleotide exchange factor (GEF), SGEF, is a
strong interacting partner of hDlg and a consequence of this
interaction is enhanced RhoG activity. We also show that a
discrete pool of Dlg is maintained in complex with E6 and SGEF
in HPV-18 positive cervical tumour-derived cells, which in turn
contributes to maintaining high levels of RhoG activity and thus
directly contributes to the invasive potential of these cells.
Results
SGEF is a novel interacting partner of hDlg
We performed a proteomic screen for Dlg interacting partners
by transfecting HA-tagged Dlg into HEK293 cells (where
endogenous hDlg levels are low) and subjecting the cell extracts
to immunoprecipitation using anti-HA antibody-conjugated
agarose beads. Total immunoprecipitates were then subjected to
mass spectroscopic analysis and the resulting protein profiles were
compared with those obtained from mock-transfected cells to
exclude non-specific interactions. As can be seen from Figure 1A,
a number of previously reported interacting partners of hDlg were
identified in this analysis, including Net1, CASK and LIN7C,
confirming these as bona fide interacting partners of hDlg [29,42].
Amongst the novel potential interacting partners identified, we
selected Src homology 3 domain-containing guanine nucleotide
exchange factor (SGEF) as a particularly interesting candidate.
This protein is a RhoG specific GEF, and has been reported to
play important roles in regulating cell-cell contact and cell
migration [43]. Furthermore, SGEF also contains a PDZ binding
motif (PBM) at its C-terminus, suggesting one means by which it
might interact with hDlg. To confirm that Dlg and SGEF can
interact, HA-tagged Dlg was over-expressed either alone or in
combination with Flag-tagged SGEF, and after 24 hrs the cells
were harvested and cellular extracts were immunoprecipitated
using anti-HA conjugated agarose beads. Co-immunoprecipitated
SGEF was detected by western blot using anti-Flag antibody. The
results in Figure 1B show that SGEF is specifically co-
immunoprecipitated with Dlg, in agreement with the proteomic
analyses. To determine whether the isolated SGEF PBM could
recognize Dlg, a peptide pull-down assay was performed using
either a biotinylated peptide corresponding to the carboxy
terminal 10 amino acids of SGEF or a control (CTRL) peptide
in which the last 4 amino acids, corresponding to the PBM
consensus, were replaced with glycine residues (Figure 1C (i)).
Immobilised peptides were then incubated with a mouse liver
lysate and bound Dlg was detected by western blotting. The results
in Figure 1C (ii) clearly show that the isolated SGEF PBM can
specifically interact with Dlg. To further determine whether
endogenously expressed hDlg and SGEF can exist in a complex
we performed a series of co-immunoprecipitation experiments in
HEK293 and HaCaT epithelial cells. In order to confirm the
correct identity of the SGEF band that we were detecting, we also
transfected an siRNA to SGEF in the HEK293 experiment. The
results in Figure 1D show clear complex formation between hDlg
and SGEF in both cell types.
The interaction between Dlg and SGEF involves both
PDZ and SH3 domains
To investigate further the mechanism of association between
Dlg and SGEF, a series of purified GST.Dlg fusion proteins
(Figure 2A) were used in pull-down assays of cell extracts from
HEK293 cells that had been transfected with a plasmid expressing
Flag-tagged SGEF. Bound SGEF was then detected by western
blot with anti-Flag antibodies. The results in Figure 2B show a
very strong interaction between wild type (wt) full-length Dlg and
SGEF, whilst no interaction was obtained with the NT region
(residues 1–222) of Dlg. In contrast, strong interaction was
obtained with a construct encompassing PDZ domains 1 and 2
(residues 1–382), with a somewhat weaker interaction with a
construct encompassing PDZ domain 1 (residues 1–276). Inter-
estingly, a significant degree of association was also obtained with
the carboxy terminal region of Dlg (residues 539–921). These
results suggest that SGEF binds to sites within the PDZ domains of
Dlg and also within the carboxy terminus, which contains an SH3
domain. As a further confirmation of these experiments, HEK293
cells were transfected with different HA-tagged constructs of Dlg,
then the cell extracts were immunoprecipitated using anti-HA
conjugated agarose beads and endogenously bound SGEF was
Author Summary
The E6 oncoproteins from cancer-causing Human Papillo-
maviruses (HPVs) all share the capacity to target cellular
PDZ domain containing proteins. The first such target of E6
to be identified was the cell polarity regulator Discs Large
(Dlg). However owing to the limited information on the
molecular basis for hDlg function, there is currently no
information on what the role of the HPV E6-Dlg interaction
might mean for the development of cervical cancer. In this
study we have identified the molecular basis by which Dlg
can regulate cell migration and invasion. This involves an
interaction with SGEF, which in turn results in enhanced
levels of RhoG activity and hence increased cell invasive
capacity. Most importantly, we show that HPV-18 and HPV-
16 E6 maintain this activity of Dlg to enhance a cell’s
invasive potential. These studies have major implications
for how E6-PDZ interactions might contribute to HPV
induced malignancy. Furthermore they also provide
compelling evidence to explain how Dlg can contribute
to the regulation of cell invasion and migration, and
indicate that certain cellular pools of Dlg have distinct
oncogenic potential.
hDlg Regulation of SGEF
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shown in Figure 2C demonstrate strong co-immunoprecipitation
between wt Dlg and SGEF with reduced, but still significant, levels
of interaction between mutants of Dlg and SGEF that encompass
just the N-terminal PDZ domains and the carboxy terminus of
Dlg.
The above results indicate that SGEF can recognize two
different sites on Dlg: the PDZ and SH3 domains. To investigate
this further, pull-down assays were again performed using purified
GST.Dlg fusion proteins and extracts from cells transfected with
Myc-tagged wt SGEF and mutants of SGEF deleted in the PBM
and SH3 domains. Bound SGEF was detected by western blot
with anti-Myc antibody. The results in Figure 2D again show
strong interaction between wt SGEF and wt Dlg, but SGEF
mutated in the PBM or SH3 domains shows reduced but still
significant levels of interaction. Interestingly, a Dlg mutant that
lacks the SH3 domain, but retains two PDZ domains (DLGNT1/
2), still binds strongly to an SGEF mutant that retains the PBM but
lacks the SH3 domain, whilst no interaction is seen with the SGEF
PBM mutant. In contrast, a Dlg mutant that only contains the
SH3 domain binds strongly to an SGEF mutant that lacks the
PBM, but not to an SGEF mutant that is deleted in the SH3
domain. Taken together these results demonstrate that the Dlg-
SGEF interaction involves both PDZ and SH3 domain recogni-
tion, and this is summarized schematically in Figure 2E.
Dlg regulates SGEF localization
Previous studies have shown that hDlg has many characteristics
of a molecular scaffold, coordinating the assembly of multi-protein
complexes within defined cellular compartments [44]. Having
Figure 1. Identification of SGEF as an interacting partner of Dlg. Panel A. HEK293 cells were transfected with HA-tagged Dlg expression
plasmid and after 24 hrs cells were immunoprecipitated using anti-HA antibody-conjugated agarose beads. The total protein complex was then
subjected to mass spectroscopy analysis. The table shows a selection of the prominent Dlg interacting proteins, together with the peptide sequences
showing SGEF as a novel interacting partner. Panel B. HEK293 cells were transfected with HA-tagged Dlg and Flag-tagged SGEF expression plasmids,
as indicated, and after 24 hrs cell extracts were immunoprecipitated using anti HA-antibody conjugated agarose beads. Dlg-bound SGEF was then
detected by western blotting using anti-Flag antibody. Panel C. Mouse liver lysate was incubated with streptavidin-Sepharose beads coupled with
biotinylated peptides corresponding to the last 10 amino acids of SGEF or control (CTRL) peptides (i) in which the last 4 amino acids were replaced by
glycine (underlined). (ii) After being washed, the samples were separated by SDS-PAGE and immunobloted with anti-Dlg1 antibodies. Panel D. HaCaT
and HEK293 cell extracts were subjected to immunoprecipitation with pre-immune, anti-SGEF or anti-Dlg antibody as indicated, and the
corresponding co-immunoprecipitating Dlg or SGEF detected by western blotting as indicated. As an additional control, HEK293 cells were also
transfected with siRNA SGEF or siRNA Luc 72 hrs prior to harvesting, thereby confirming the identity of the SGEF protein detected with the anti SGEF
antibody.
doi:10.1371/journal.ppat.1002543.g001
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determine whether Dlg could modulate the pattern of SGEF
expression. To do this, HEK 293 cells were transfected with Myc-
tagged SGEF alone or in combination with increasing amounts of
plasmid expressing HA-tagged Dlg. After 24 hrs, NP-40 soluble
and insoluble cellular extracts were prepared, and the pattern of
SGEF expression was analysed by western blot using anti-Myc
antibody. The results in Figure 3A demonstrate that Dlg appears
to have no major effect on the NP-40 soluble pool of SGEF, but
increases the amount of SGEF in the NP-40 insoluble pool quite
dramatically. Since we have shown that the association between
the Dlg and SGEF involves both PDZ and SH3 domain
recognition, we next investigated which of these interactions was
responsible for this phenotype. To do this we repeated the assay,
but included mutants of SGEF deleted in the PBM or SH3
domain. The results in Figure 3B again show that Dlg has no
significant effect upon the levels of SGEF expression in the NP-40
soluble fraction of the cell, whilst wt SGEF increases dramatically
in the insoluble portion. Interestingly, Dlg has minimal effect upon
the solubility of the SGEF DPBM mutant, whereas the DSH3
mutant of SGEF behaves like the wt protein, and there is a
significant increase in the NP-40 insoluble pool of this mutant in
the presence of Dlg. Both the DPBM and DSH3 mutants display
significant levels of expression within the NP-40 insoluble fraction
in the absence of ectopic Dlg, and this degree of mislocalisation,
which has been reported previously [45], may be related to their
relatively increased levels of expression. However, taken together
these results demonstrate that although the interaction between
Dlg and SGEF involves the PDZ and SH3 domains, it is only the
PBM-PDZ domain interaction that affects the pattern of SGEF
expression in response to ectopically expressed Dlg. To further
investigate the effects of hDlg upon SGEF, we analyzed SGEF
levels in epithelial cells where hDlg expression was stably ablated,
and compared this with control cells and cells in which targeting
vector-resistant rat Dlg was re-expressed. The results in Figure 3C
show that loss of hDlg results in a dramatic decrease in total SGEF
levels, most particularly in the NP-40 insoluble fraction of the cell.
Similar effects of Dlg on SGEF were observed in the total lysates
(Figure 3D), and in both cases re-introduction of rat Dlg restored
the levels of SGEF expression.
To determine the particular cellular compartment to which
SGEF was being recruited by Dlg, HEK293 cells were transfected
with expression plasmids encoding HA-tagged Dlg and Flag-
tagged SGEF. Cell fractionations were performed to divide the
Figure 2. The interaction between Dlg and SGEF involves PBM-PDZ and SH3-SH3 domain recognition. Panel A. Diagrammatic
representation of the Dlg deletion mutants used in this study. Panel B. HEK 293 cells were transfected with Flag-tagged SGEF expression plasmid and
cell extracts made after 24 hrs. These were then incubated with a panel of GST.Dlg fusion proteins encompassing different domains of the Dlg
protein and GST alone as a negative control. Bound SGEF was then detected by western blotting using anti-Flag antibody (upper panel). The middle
panel shows the Ponceau stain of the membrane confirming similar levels of GST protein expression, whilst the bottom panel shows the input of
SGEF used in each assay. Panel C. HEK293 cells were transfected with HA-tagged wild type Dlg and two mutants encompassing the N and C terminal
halves of the protein. After 24 hrs the cells were extracted and Dlg precipitated using anti-HA antibody. The co-immunoprecipitated endogenously
expressed SGEF was then detected by western blot using anti-SGEF antibody (upper left panel). Input proteins are shown in the two right panels and
the lower left panel shows the immunoprecipitated Dlg (indicated by arrows). Panel D. HEK293 cells were transfected with myc-tagged wild type
SGEF and mutants deleted in the PDZ binding motif and the SH3 domain. After 24 hrs cell extracts were made and incubated with purified GST fusion
protein, consisting of GST alone, wild type Dlg and the N and C terminal halves of Dlg. Bound SGEF was detected by western blot using anti-myc
antibody (upper panel). The lower panel shows the Ponceau stain of the membrane demonstrating the levels of GST protein expression with arrows
indicating the relevant full-length GST fusion proteins. Panel E. Schematic summarizing the results of the interaction assays, demonstrating
interaction between the Dlg PDZ1 and PDZ2 domains with the SGEF PBM plus association between the SGEF and Dlg SH3 domains.
doi:10.1371/journal.ppat.1002543.g002
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Patterns of Dlg and SGEF expression were then ascertained by
western blotting and the results are shown in Figure 4A. As can be
seen, in the presence of ectopically expressed Dlg there is a clear
redistribution of SGEF from cytosolic and nuclear fractions into
the cytoskeletal fraction of the cell. We wanted to further confirm
the co-localization of DLG and SGEF by immunofluorescence.
HaCaT cells were transfected with HA-DLG and Flag-SGEF,
either alone or in combination. After 24 hrs, the cells were fixed
and stained for DLG and SGEF. The results in Figure 4B and
Figure S1 show that over expressed SGEF has a diffuse pattern of
expression, with significant amounts present within the nucleus.
However when Dlg was co-transfected with SGEF, there was a
marked decrease in the amount of SGEF in the nucleus, and a
concomitant increase within the cytoplasm, with both Dlg and
SGEF showing a high degree of co-localisation within the
cytoplasmic cytoskeleton.
The interaction between Dlg and SGEF enhances
endogenous RhoG activity
SGEF has been shown to be a GEF specific for RhoG [45]. To
test whether the interaction and the recruitment of SGEF to the
cytoskeleton by Dlg has any biological consequences in terms of
SGEF regulation of RhoG, we proceeded to monitor the levels of
RhoG activity, as determined by its ability to interact with the
downstream target, ELMO [46]. To do this we performed an
affinity pulldown that specifically precipitates active GTP-bound
RhoG, as previously described [45]. The results obtained in
Figure 5A, together with the quantifications from multiple assays
in Figure 5B, show no alteration in total RhoG levels under the
different assay conditions, whilst there is a significant increase in
the levels of ELMO-bound active RhoG in cells transfected with
SGEF, and this is in agreement with previous studies [45].
However, most strikingly, co-transfection of Dlg and SGEF results
in a dramatic increase in the amount of active RhoG, suggesting
that Dlg can increase SGEF activity with respect to its downstream
effector, RhoG. As an additional verification of these studies, we
also monitored RhoG activity in a similar manner in cells in which
hDlg expression had been stably ablated. The results of the pull-
down assays are shown in Figure 5C and clearly show that, whilst
there are no changes in total levels of RhoG expression, there is a
greatly reduced level of active RhoG present within the hDlg-
depleted cells in comparison with the different sets of control cells,
and this increases in the rescued rat Dlg-expressing cells. In
conclusion, these data demonstrate that hDlg positively regulates
SGEF- induced RhoG activity in epithelial cells.
HPV18 E6/E7 maintains high levels of RhoG activity in a
Dlg/SGEF dependent manner
Having shown that hDlg influences the activity of SGEF and
RhoG, we wanted to determine what effects HPV-18 E6 might
have upon this. To do this we first analysed the levels of RhoG
activity in HPV-18 positive cervical tumour derived HeLa cells.
GST-ELMO pull-downs were done using extracts from cells in
which E6/E7 and hDlg1 expression had been ablated by siRNA
transfection. The results and quantitations from multiple assays in
Figure 6A show a number of interesting features. Firstly, RhoG
activity levels are constitutively high in the control transfected
cells. Ablation of E6/E7 expression results, as expected, in an
increase in the total levels of hDlg expression and also, most
Figure 3. Dlg regulates the cellular localisation of SGEF. Panel A. HEK293 cells were transfected with myc-tagged SGEF expression plasmid
together with increasing amounts of HA-tagged Dlg expression plasmid. After 24 hrs cells were extracted into soluble (left panel) and insoluble (right
panel) fractions. Changes in the patterns of SGEF localisation were detected by western blot using anti-Myc antibody and Dlg was detected using
anti-HA antibody. The levels of b-gal expression are also shown as a marker for transfection efficiency and loading control. Panel B. HEK293 cells were
transfected with the Myc-tagged SGEF expression plasmids together with a HA-tagged Dlg expression plasmid. After 24 hrs the cells were extracted
into soluble and insoluble fractions and the pattern of expression determined by western blot analysis. b-gal expression was used as a marker for
transfection efficiency and a loading control. Panel C. HaCaT cells stably selected with control targeting plasmid (TR2), shDlg targeting plasmid, and
cells targeted for shDlg but rescued with rat Dlg were analysed for the pattern of SGEF expression in the soluble and insoluble fractions by western
blotting with anti-SGEF antibody. a-Actinin was used as a loading control. Note the complete loss of expression of SGEF from the insoluble fraction of
the cell upon hDlg ablation. Panel D. Western blot analysis of SGEF expression levels in the total cell lysates prepared from stable cell lines used in
Panel C.
doi:10.1371/journal.ppat.1002543.g003
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active RhoG. However, ablation of the residual hDlg alone, by
siRNA transfection or in combination with siRNA E6/E7 also
results in a dramatic decrease in the levels of active RhoG. These
results suggest that high levels of RhoG activity in HeLa cells are
dependent upon the presence of both E6/E7 and hDlg, even
though certain pools of hDlg are also degraded by the HPV-18 E6
oncoprotein. This would therefore suggest that E6 is potentially
recruiting or preserving a pool of hDlg that contributes to
maintaining elevated SGEF activity. To investigate this possibility
we analysed the levels of hDlg expression in the NP-40 soluble and
insoluble pools of HeLa cells following ablation of E6/E7
expression. The results in Figure 6B(i) show that, as expected,
there is a significant increase in the levels of hDlg expression in the
NP-40 soluble fraction upon removal of E6//E7 expression.
However, in the insoluble fraction there is a significant decrease in
the levels of both hDlg and SGEF expression, suggesting that
whilst certain pools of hDlg are targeted for degradation by E6,
others are either actively maintained or unaffected. We also
wanted to determine if the pattern of SGEF expression in other
HPV positive cells was similarly dependent upon E6/E7
expression. To do this we analysed HPV-16 positive CaSki cells.
The results in Figure S2 confirm that loss of E6/E7 expression also
results in a loss of SGEF from the NP-40 insoluble pool in these
cells.
To further verify that the existence of the NP-40 insoluble pool
of SGEF was dependent upon the presence of hDlg, we performed
an siRNA Dlg transfection in HeLa cells and the results in
Figure 6B(ii) show that whilst loss of hDlg has a minimal effect
upon the levels of SGEF in the NP-40 soluble fraction of the cell,
there is a complete loss of SGEF from the NP-40 insoluble pool.
Taken together these results imply that these NP-40 insoluble
Figure 4. Dlg recruits SGEF to the cytoskeletal network. Panel A. HEK293 cells were transfected with HA-tagged Dlg and Flag-tagged SGEF
expression plasmids as indicated and after 24 hrs cells were extracted and divided into cytosolic, membrane, nuclear and cytoskeletal fractions. The
pattern of Dlg and SGEF expression was then determined by western blotting with anti-HA and anti-Flag antibodies respectively. Loading controls
confirming the integrity of the differential extractions are a-tubulin, E-cadherin, p84 and vimentin for the cytosolic, membrane, nuclear and
cytoskeletal fractions respectively. Panel B. HaCaT cells transfected with HA-Dlg, Flag-SGEF or co-transfected with the two cDNAs were fixed and
processed for immunofluorescence with anti-Flag to detect SGEF and anti-HA to detect Dlg. i) Single HA-Dlg transfection. ii) Single Flag-SGEF
transfection. iii) Co-transfection with Dlg in red and SGEF in green. The arrows indicate discrete areas of co-localisation within cytoplasmic and
membrane sites.
doi:10.1371/journal.ppat.1002543.g004
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favourable for maintenance of the malignant phenotype.
It is noteworthy from these experiments that loss of E6/E7 also
appears to result in a general overall decrease in the levels of
SGEF expression (Figures 6A and 6B(i)). Previous studies have
shown that SGEF is responsive to regulation by E2F-1 [47], and
we reasoned that loss of SGEF expression might in part be due to
an indirect effect of E7 affecting the levels of E2F-1 activity via its
association with pRb [8,48]. To investigate this we repeated the
assay but used two different siRNAs, one directed against just the
HPV-18 E6, with the other against both E6 and E7. The results in
Figure 6C show that loss of E6 alone has minimal effect on total
SGEF levels, whilst loss of both E6 and E7 results in a decrease in
SGEF expression, consistent with the notion that high levels of
SGEF expression are being maintained in part by the E7
oncoprotein.
HPV-18 E6 can exist in complex with hDlg1 and SGEF
To determine whether the residual Dlg protein in HeLa cells
was still in complex with SGEF we performed a series of
immunoprecipitation analyses. HeLa cells were immunoprecipi-
tated using either a pre-immune antibody or anti SGEF antibody,
and complexed hDlg was detected using anti-hDlg-1 antibodies.
The results in Figure 7A show clear interaction between hDlg and
SGEF in HeLa cells. This raised the possibility that E6 might also
be present in this complex, so the immunoprecipitates were also
analysed for the presence of HPV-18 E6, and, as can be seen from
Figure 7A, co-immunoprecipitation of E6 with hDlg and SGEF
was also observed. Similarly, when hDlg-1 was immunoprecipi-
tated, both SGEF and HPV-18 E6 could also be detected in the
co-immunoprecipitating complexes (Figure S3). We also examined
whether hDlg and SGEF could be found in a complex in other
HPV transformed cells. To do this hDlg was immunoprecipitated
from HPV positive cervical tumour derived Me180 and CaSki
cells, as well as from the HPV-16 non-tumourigenic immortalized
W12 cells, and complexed SGEF was detected by western blotting.
The results in Figure 7B also confirm the interaction between Dlg
and SGEF in these other HPV positive cell lines, although the
interaction was harder to detect in the W12 cell line.
Since the interaction between E6 and Dlg involves PDZ domain
recognition, in a manner similar to that linking Dlg and SGEF, we
wanted to determine whether the ability of E6 to complex with
Dlg and SGEF was also dependent upon its PBM. To do this cells
were transfected with Dlg and SGEF expression constructs, and
cell extracts were used in GST pull -down assays with wild type
HPV-18 E6 and HPV-18 E6 mutated in the PBM. Bound proteins
were detected by western blotting and the results obtained are
shown in Figure 7C. As can be seen, the interaction between E6
and Dlg is strictly PDZ domain-dependent, in agreement with
previous studies [16]. Most importantly however, SGEF is also
pulled down by 18E6, but only when Dlg is present and in a PBM
dependent manner, although the GST. DPDZ18E6 is expressed at
Figure 5. Dlg enhances RhoG activity in an SGEF dependent manner. Panel A. HEK293 cells were either transfected with vector or HA-tagged
Dlg and Flag-tagged SGEF as indicated. After 24 hrs cell extracts were made which were then incubated with purified GST-ELMO to pull down active
RhoG which was detected by western blot analysis. The three lower panels show total protein inputs for RhoG, Dlg and SGEF. Panel B. Graph showing
the quantification from multiple GST-ELMO pull-downs, showing the fold change in the levels of RhoG activity under the different experimental
conditions. Error bars represent 6SD of three independent experiments Panel C. Extracts from HaCaT cells stably ablated for hDlg expression (shDlg)
either with or without Dlg rescue expression were used in a GST-ELMO pulldown assay to determine RhoG activity. Extracts from untreated HaCaT
cells or HaCaT cells stably expressing control shRNA(TR2) were used as control.
doi:10.1371/journal.ppat.1002543.g005
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existence of a complex involving Dlg, SGEF and HPV-18 E6.
To investigate this further we performed a series of transient
overexpression experiments in 293 cells. The cells were transfected
with an untagged E6 expression vector, together with Dlg and
SGEF. Cell extracts were divided into NP-40 soluble and insoluble
pools and the levels of expression of E6, Dlg and SGEF were
analysed by western blotting. The results in Figure 8 demonstrate
a number of interesting features. Co-expression of Dlg and SGEF
results in a marked accumulation of both proteins in the NP-40
insoluble compartment. When Dlg and E6 are co-transfected, E6
induces a dramatic decrease in the levels of Dlg, particularly in the
NP-40 soluble fraction of the cells. However, the levels of Dlg are
largely unaffected by E6 in the NP-40 insoluble pool when SGEF
is also present. Furthermore, E6 also becomes localized to this NP-
40 insoluble fraction when both SGEF and Dlg are present. Taken
together, these results demonstrate that E6, Dlg and SGEF can
exist in complex within the NP-40 insoluble fraction of the cell,
and that this is dependent upon the ability of E6 to bind Dlg in a
PDZ-domain dependent manner.
To determine whether E6 overexpression could influence the
pattern of SGEF expression, we co-transfected HA-tagged HPV-
18 E6 and Flag-tagged SGEF into HaCaT epithelial cells, and
after 24 hrs analysed their respective patterns of expression by
immunofluorescence and confocal microscopy. The results in
Figure S4 show that SGEF by itself has a largely nuclear pattern of
expression, similar to that seen in Figure 4B. However, in the
presence of ectopically expressed E6 there is a marked
accumulation of SGEF within the cytoplasmic portion of the cell,
suggesting that E6 can affect the pattern of SGEF localization.
hDlg and SGEF both contribute to the invasive capacity
of HPV transformed cells
HeLa cells are highly tumourigenic and exhibit invasive
capacity in matrigel assays [49]. Based upon the above results,
we reasoned that this invasive capacity might be dependent upon
the active Dlg/SGEF pool that is maintained by E6/E7
expression. To investigate this we proceeded to perform a series
of matrigel invasion assays using HeLa cells in which either E6/
E7, hDlg or SGEF expression was ablated by siRNA transfection.
Figure 6. High levels of RhoG activity in HPV-18 transformed cells is hDlg and HPV -dependent. Panel A. HeLa cells were transfected with
siRNAs against luciferase (Luc) control, E6/E7, hDlg or SGEF as indicated. After 72 hrs cell extracts were then incubated with purified GST.ELMO to
determine the levels of active RhoG, which was detected by western blotting (upper panel). The lower panels show input levels of total RhoG, hDlg,
SGEF, p53 and a-Actinin. Also shown is the Ponceau stain of the membrane showing constant levels of GST.ELMO. The graph shows the
quantifications from multiple GST.ELMO pull-downs, and shows the fold change in the levels of RhoG activity under the different experimental
conditions. Error bars represent +/2 SD of four independent experiments. Note the modest decrease in active RhoG following the removal of E6/E7
and the dramatic decrease following removal of hDlg. Panel B. HeLa cells were transfected with control siRNA (Luc) siRNA to E6/E7 (i) or siRNA to
hDlg-1 (ii) and were then analysed for the levels of hDlg, SGEF, and p53 expression after 72 hrs in the insoluble and soluble compartments of the cell.
a-Actinin was used as a loading control. Note the marked increase in hDlg levels in the soluble fraction with concomitant decrease in the insoluble
fraction following E6/E7 removal, which is also accompanied by a decrease in SGEF levels in this compartment and a similar loss of SGEF in the
insoluble compartment is seen following siRNA ablation of hDlg-1 expression. Panel C. HeLa cells were transfected with control siRNA (Luc), siRNA to
E6 (si18E6intronic) or siRNA to E6/E7 and were then analysed for levels of expression of SGEF and p53 in total cell lysates after 72 hrs. a-Actinin was
used as a loading control.
doi:10.1371/journal.ppat.1002543.g006
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the cells were trypsinised and counted, and equal numbers of cells
were inoculated into matrigel invasion chambers. At the same
time, the efficiency of the siRNAs was determined by western
blotting for the relevant target protein (Figure 9A). Chambers were
left overnight at 37uC and the number of cells invading the lower
chamber was counted the following day. The collated results from
multiple assays are also shown in Figure 9A. Not surprisingly, loss
of E6/E7 expression results in a dramatic decrease in the invasive
capacity of these cells. However, loss of either hDlg or SGEF also
results in a significant decrease in the capacity of these cells to
invade the matrigel. We also repeated this assay in HPV-16
positive CaSki cells and the results shown in Figure 9B also
confirm that continued expression of hDlg and SGEF contribute
directly to the invasive potential of these cells. These results
demonstrate that, in the context of HPV-induced malignancy, the
residual levels of hDlg found within HPV-18 positive HeLa cells
and HPV-16 positive CaSki cells actually contribute directly to the
invasive potential of these cells, most likely through up-regulation
of SGEF and RhoG activity.
Finally we wanted to determine whether Dlg and SGEF could
also contribute to the invasive potential of other non-HPV
Figure 7. HPV-18E6, hDlg and SGEF exist as a complex. Panel A. HeLa cells were seeded in 10 cm
2 dishes. After 24 hrs, cell extracts were
prepared and immunoprecipitated using either the control antibody or the SGEF antibody. hDlg and HPV18E6 bound to the SGEF were detected
using the anti-Dlg and anti-E6 antibodies respectively. The immunoprecipitated SGEF was detected using anti-SGEF antibody. The bottom 3 lanes
show the input levels for hDlg, HPV18E6 and SGEF used in this assay. Panel B. HPV positive W12, Me180 and CaSki cells were seeded on 10 cm
2 dishes
and cellular extracts immunoprecipitated using either control antibody or anti-hDlg-1 antibody. The Dlg bound SGEF was detected by western
blotting with the anti-SGEF antibody and the immunoprecipitated Dlg was detected using the anti-Dlg antibody. The right two lanes in each panel
show the input levels (20%) of SGEF and Dlg used in the control and Dlg immunoprecipitates. Panel C. HEK 293 cells were transfected with HA-tagged
Dlg and Myc-tagged SGEF expression plasmids either alone or in combination and the cell extracts made after 24 hrs. These were then incubated
with GST-wt18E6 or GST-DPDZ18E6 and GST alone as a negative control. Bound Dlg was then detected by western blotting using anti-HA antibody
(upper panel), bound SGEF was detected using anti-Myc antibody (second panel). The third and fourth panels shows the input of Dlg and SGEF used
in this assay. The bottom panel shows the Ponceau stain of the membrane showing the levels of GST protein expression.
doi:10.1371/journal.ppat.1002543.g007
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of siRNA induced ablation of hDlg-1 and SGEF upon the invasive
capacity of non-small cell lung cancer derived H1299 cells. The
results obtained are shown in Figure S5 and demonstrate that both
hDlg and SGEF also contribute towards the invasive potential of
these cells. This suggests that both SGEF and Dlg might be
involved in the invasion of diverse tumour types. However, in the
context of HPV induced malignancy, where a subset of Dlg is
normally degraded by E6, the virus maintains this invasive
potential by increasing the levels of SGEF expression and by
preserving this SGEF bound pool of Dlg.
Discussion
hDlg was the first PDZ domain-containing substrate of HPV-18
E6 to be identified, and a number of studies have shown that one
of the consequences of this interaction is the proteasome-mediated
degradation of hDlg. However E6-mediated degradation of hDlg
is not complete, and significant levels of hDlg expression remain in
cervical tumour-derived cell lines, raising questions about the role
of hDlg in HPV-induced malignancy. As a means of understand-
ing hDlg function more fully, and by analogy its role in HPV-
induced pathogenesis, we used a proteomic approach to look for
Figure 8. HPV18E6 does not degrade the NP-40 insoluble pool of hDlg in the presence of SGEF. HEK293 cells were transfected with HA-
tagged Dlg, Myc-tagged SGEF, untagged HPV18E6 expression plasmids either alone or in different combinations as indicated. After 24 hrs the cells
were extracted into NP-40 soluble and NP-40 insoluble fractions and the patterns of expressions of Dlg, SGEF and E6 determined by western blot
analysis. b-gal expression was used as a marker for transfection efficiency and a loading control.
doi:10.1371/journal.ppat.1002543.g008
Figure 9. The hDlg/SGEF module is required for the invasive capacity of HeLa and CaSki cells. The cells (HeLa in Panel A and CaSki in
Panel B) were transfected with siRNAs to Luciferase (Luc), E6/E7, hDlg or SGEF and after 72 hrs the cells were harvested and equal numbers plated
onto Matrigel invasion chambers. After overnight incubation the numbers of invading cells in the lower chamber were counted. The graphs show the
fold change in the numbers of invading cells from multiple assays, where siLuc- transfected cells were scored as the reference point. Error bars
represent 6SD of multiple experiments. The right hand panels show the western blot analysis of the levels of expression in total cell extracts of hDlg,
p53 and SGEF following siRNA transfections performed in parallel with the invasion assays. a-Actinin is shown as the loading control.
doi:10.1371/journal.ppat.1002543.g009
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characterised one of these hDlg interactions; that with the RhoG
specific exchange factor, SGEF, and determined the relevance of
this association for the regulation of RhoG activity and for HPV-
induced malignancy.
SGEF was initially found in a screen for androgen-responsive
genes in human prostate cancer cells [50]. It contains an amino-
terminal proline-rich region (Pro), a Dbl homology (DH) domain
followed by a Pleckstrin homology (PH) domain, an SH3 domain
and a putative PBM [50]. There are several studies reporting the
interaction between PDZ domain- containing proteins of the
MAGUK family and cellular GEFs, and in most cases, the
interaction is mediated through PDZ domain recognition
[51,29,52,53]. For instance, Net1, a RhoA specific exchange
factor, interacts through its PBM with the tumour suppressor
proteins of the Dlg family, including hDlg/SAP97, SAP102, and
PSD95 [29]. Here we provide evidence that hDlg and SGEF can
interact in a number of different cell types. Mutational analyses
demonstrate that the interaction between hDlg and SGEF occurs
through two distinct interaction sites and involves both PDZ
domain and SH3 domain recognition, although the PBM-PDZ
domain interaction appears to be the stronger of the two. The
precise stoichiometry of the interaction remains to be determined,
as at present it is unclear whether two molecules of SGEF can bind
hDlg simultaneously, or whether a single molecule of SGEF binds
to hDlg through two separate domains.
From a physiological point of view, the PDZ-PBM interaction
between hDlg and SGEF seems to be the most important, since
the ability of hDlg to affect the pattern of SGEF expression is PDZ
domain-dependent and does not seem to be influenced by SH3
domain recognition. A number of previous studies have proposed
that hDlg can function as a molecular scaffold for many of its
target proteins. This would appear to hold true in part with respect
to SGEF. Thus, overexpressed Dlg induces a marked relocalisation
of SGEF from the nuclear/cytosolic compartments into an
insoluble cytoplasmic cytoskeletal compartment. These studies
were also supported by a series of ablation experiments where loss
of hDlg results in a decrease in the levels of SGEF expression
within the insoluble cytoskeletal fraction. Taken together, these
studies demonstrate that hDlg regulates SGEF localization
through the PDZ-PBM interaction.
SGEF activates RhoG efficiently in vitro and in vivo [45] and
this activity appears to be highly dependent upon the levels and
localization of hDlg. Thus, whilst overexpressed SGEF can
activate endogenous RhoG, in agreement with previous studies
[45], addition of Dlg greatly augments this activity of SGEF. The
positive influence of hDlg on SGEF activity was further confirmed
in HaCaT epithelial cells where stable knock-down of hDlg
expression also down-regulated the activation of endogenous
RhoG; an effect that was reversed upon re-introducing rat Dlg.
These results provide a clear explanation for previously reported
studies implicating hDlg in the control of cell migration, with the
SGEF interaction being a prime candidate for the molecular
mechanism by which hDlg regulates this process.
We then proceeded to investigate the implications of the hDlg/
SGEF regulatory complex for the development of cervical
malignancy, where the HPV E6 oncoprotein has previously been
shown to target hDlg for degradation [14,54,16]. In order to
determine whether E6 could have any influence on the activity of
the hDlg/SGEF/RhoG signaling network, we made use of HPV-
18 containing HeLa cells that are derived from a cervical tumour.
Not surprisingly, siRNA ablation of SGEF expression greatly
reduces the levels of RhoG activity in these cells, demonstrating
that active RhoG in HeLa is SGEF dependent. Surprisingly,
silencing of HPV18E6/E7 expression also down-regulates the
levels of RhoG activation. This seems somewhat paradoxical, since
hDlg levels show a significant increase upon removal of E6
expression. In order to determine whether the residual hDlg in
HeLa cells was in any way influencing SGEF activity, we
performed transient siRNA to hDlg and also found a striking
decrease in the levels of RhoG activity, similar to that seen with
the removal of E6/E7 or SGEF expression. These results
demonstrate that high levels of RhoG activity in HeLa are
dependent upon SGEF, hDlg and E6/E7 expression. This also
suggests that the residual hDlg in HeLa cells that is not degraded
by E6 can influence RhoG activity, and also implies that this pool
of hDlg is either unaffected by E6 or is actively maintained by the
viral oncoproteins. To investigate this we performed cell
fractionation assays following removal of E6/E7 expression, and
found stabilization of hDlg only within the NP-40 soluble fraction
of the cell. Interestingly, there was a significant concomitant
decrease in the levels of hDlg in the NP-40 insoluble pool and this
was accompanied by an equivalent decrease in SGEF levels.
Similar results were also obtained in HPV-16 positive CaSki cells,
where we found that the presence of the NP-40 insoluble pool of
SGEF was also dependent upon continued E6/E7 expression.
These results indicate that whereas NP-40 soluble pools of hDlg
are degraded by E6, the insoluble cytoskeletal-bound forms of
hDlg/SGEF are actually maintained by the presence of the HPV
oncoproteins. This was also confirmed in transient overexpression
experiments where E6 actively degrades NP-40 soluble forms of
Dlg, but has minimal effect upon the NP-40 insoluble forms when
SGEF is also overexpressed; interestingly E6 would also appear to
be present in this NP-40 insoluble compartment under these
conditions. These results imply that E6 may exist in complex with
the Dlg and SGEF, and indeed, co-immunoprecipitation analyses
in HeLa cells support this. To gain insight into how this complex
might be formed we performed pull-down assays using wild type
and a DPBM mutant of E6. In these assays we could clearly see
that E6 could pull down SGEF from cell extracts only in the
presence of Dlg, and only if it had an intact PBM. Taken together,
these results indicate that E6 can exist in complex with both hDlg
and SGEF in HPV-18 transformed cells and that this complex is
responsible for the high levels of RhoG activity found in these cells.
During the course of these studies we also noticed that loss of
E6/E7 expression has a generally deleterious effect upon the levels
of SGEF expression. Using different targeting siRNAs we found
that loss of E6 alone has minimal effect upon total SGEF levels of
expression, whilst loss of both E6 and E7 results in a marked
decrease in the levels of SGEF expression. This suggests that E7
may contribute directly to maintaining high levels of SGEF
expression in these HPV transformed cells. Indeed, SGEF is
subject to regulation by E2F-1 [47], suggesting that one potential
means by which E7 could achieve this is via degradation of pRb
and increased levels of E2F-1 activity [8,48]. These studies also
provide a further demonstration of the cooperativity in function
between E6 and E7. In this case, E7 contributes by maintaining
high levels of SGEF expression, whilst E6 contributes by retaining
a pool of Dlg/SGEF favourable for maintaining high levels of
RhoG activity.
Finally, we wanted to determine whether this insoluble
cytoskeletal bound pool of hDlg and SGEF was biologically
relevant in the context of the invasive capacity of HPV
transformed cells. Using matrigel invasion assays we found that
invasion was critically dependent upon the continued expression of
E6 and E7 in HPV-18 and HPV-16 positive tumour-derived cell
lines. Importantly, we also found that both hDlg and SGEF play
vital roles and are essential for the optimal invasive potential of
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RhoG is also required for cell migration and invasion of HeLa cells
[55] and breast cancer cells [56], and also with our data showing
that the invasive potential of a HPV negative lung cancer-derived
cell line is also dependent upon Dlg and SGEF expression. Taken
together, these studies demonstrate that the SGEF/hDlg/RhoG
module can directly control a tumour cell’s invasive potential.
Based on this we can propose a model where hDlg recruits SGEF
to the cytoskeleton, resulting in increased levels of RhoG
activation and increased levels of invasion. In the context of
HPV-induced malignancy a significant amount of hDlg is
degraded by E6, however this cytoskeletal bound form of hDlg
in complex with SGEF is actively maintained by the combined
action of E6 and E7, thereby maintaining the invasive potential of
the cells. Whilst it would be naı ¨ve to assume that this is the only
activity required for the invasiveness of HPV transformed cells, it
nonetheless demonstrates that loss of either hDlg or SGEF alone is
sufficient to abolish their invasive capacity.
At present we have no information on what the role of the E6-
Dlg interaction might have with respect to the viral life cycle,
although loss of PDZ binding capacity in the context of the viral
genome is highly deleterious [57,58]. It is hard to envisage how
effects on cell invasive potential would be of relevance to the viral
life cycle, and thus this particular readout may simply reflect
downstream effects of malignancy. However, it is intriguing to
note that RhoG activity has been implicated in the control of
proliferation in stem cell-like neuronal cells [59] and in
differentiation in the context of Trio induced neurite outgrowth
[60].Therefore it is possible that in the HPV-infected keratinocyte,
activation of the RhoG pathway may also induce cell proliferation
with obvious benefits to the viral life cycle. Future studies will be
aimed at addressing these issues.
Materials and Methods
Cell culture and transfections
HEK293 (Human embryonic kidney) cells, non-small cell lung
cancer H1299 cells, HaCaT epithelial cells, HPV-18 positive
HeLa, HPV-68b positive Me180 cells and HPV-16 positive CaSki
cells were grown in DMEM supplemented with 10% fetal bovine
serum, penicillin–streptomycin (100 U/ml) and glutamine
(300 mg/ml). HPV-16 positive W12 cells were grown in F12
DMEM supplemented with 5% fetal bovine serum. Cells were
transfected using the standard calcium phosphate precipitation or
Lipofectamine 2000 (Invitrogen). HaCaT stable Dlg knockdown
cells have been described previously [61].
Plasmid constructs
The HA-tagged wild type and mutant DLG expression
constructs have been described previously [62]. The mutant
DLG constructs used in this study are as follows: HA-DLG-
NTPDZ1-2 refers to aa 1–382; HA-CT refers to aa 539–921.
GST-wtDLG refers to aa 1–921; GSTDlg-NT: aa 1–222; GST-
DlgNT1: aa 1–276; GSTDlgNT1/2: aa 1–382. The pGEX-
HPV18E6, the untagged pCDNA HPV18E6, pCDNA HA-tagged
HPV18E6 constructs and the GST-wt18E6 have been described
previously [63,64] and GST-DPDZ18E6 construct was generated
using Gene Tailor Site directed Mutagenesis System kit (Invitro-
gen). Flag-tagged wtSGEF was a kind gift from Jayesh C. Patel
(Section of Microbial Pathogenesis, Yale University School of
Medicine, Boyer Center for Molecular Medicine, New Haven).
Myc-tagged constructs of SGEF: wtSGEF, DPDZSGEF and
DSH3SGEF [45] were cloned into pCMVmyc into EcoRI and
BamHI sites (Clontech). The GST-ELMO construct was a kind
gift from Dr. Keith Burridge (Department of Cell and Develop-
mental Biology, University of North Carolina, USA).
Antibodies
Primary antibodies used were mouse anti-HA monoclonal
antibody (Roche), mouse anti-Myc (Santa Cruz), rabbit anti-SGEF
(Sigma), mouse anti-RhoG (Millipore), mouse monoclonal anti-a-
tubulin (Sigma); mouse monoclonal anti-p53 (DO-1), rabbit
polyclonal anti-a-actinin (Santa Cruz), mouse monoclonal anti-
Dlg (Santa Cruz) mouse monoclonal anti-p84 (Abcam) mouse
anti-b-galactosidase monoclonal antibody (Promega), mouse
monoclonal anti-HPV18E6 (Arbor Vita Corporation), mouse
anti-vimentin monoclonal antibody (Santa Cruz) and the second-
ary anti-mouse and anti-rabbit antibodies were conjugated to
horseradish peroxidase (Dako). The proteins were visualized by
enhanced chemiluminesence (GE Healthcare) according to the
manufacturer’s instructions.
Western Blot analysis
Fortotalcellularlysatepreparation,cellswerelysedin26sodium
dodecyl sulfate (SDS) sample buffer (100 mM Tris HCl [pH 6.8],
200 mM dithiothreitol [DTT], 4% SDS, 20% glycerol, 0.2%
bromophenol blue) and for the soluble and insoluble cellular lysate
preparation, cells were lysed with a extraction buffer (E1A)
containing 25 mM HEPES pH 7.0, 0.1% NP-40, 150 mM NaCl,
protease inhibitor cocktail I (Calbiochem). The extracts were
allowed to stand on ice for 30 min, following which the lysates were
clarified by centrifugation. The supernatant was collected in fresh
tubes as the NP-40 soluble cellular fraction whilst the pellet was
resuspended in SDS PAGE sample buffer and sonicated briefly; this
was used as the NP-40 insoluble fraction. Cell lysates, typically
50 mg, were subjected to SDS-PAGE and then electrophoretically
transferred to nitrocellulose membranes (Schleicher and Schuell).
The membranes were blocked at 37uC for 1 h in 10% milk-
phosphate-buffered saline (PBS), except for those probed with anti-
SGEF and anti-RhoG antibodies, which were blocked in 5% milk-
TBS with 0.1% Tween20. The blots were incubated with the
appropriate primary antibodies diluted in the washing buffer (10%
milk-PBS, 0.5% Tween 20), except for the anti-SGEF and anti-
RhoG antibodies, which were diluted in 5% milk-TBS and 0.1%
Tween 20. The incubation times were 2 h at room temperature for
all antibodies, except for the anti-SGEF, anti-RhoG and anti-E-
cadherin, which were incubated overnight at 4uC. After several
washes, the membranes were incubated with the appropriate
horseradish peroxidase (HRP)-conjugated secondary antibody
(Dako) for 1 h at room temperature. After extensive washing, the
blots were developed with the enhanced chemiluminescence (ECL)
or ECL Plus reagent (GE Healthcare) according to the manufac-
turer’s instructions. Protein band intensities in the case of GST-
ELMO pull down assays were quantitated using ImageJ software.
Immunoprecipitation and mass spectrometry analysis
HEK293 cells were transfected with the appropriate plasmids.
After 24 h, cells were extracted in mass spectrometry lysis buffer
(50 mM HEPES, pH 7.4 [at 4uC], 150 mM NaCl, 50 mM NaF,
1 mM EDTA, 0.25% NP-40), and extracts were incubated with
anti-HA beads (Sigma) for 2 to 3 h on a rotating wheel at 4uC.
The beads were then extensively washed, dried, and subjected to
proteomic analysis as described previously [64].
Peptide pull-down and GST pull-down assays
Peptide pull-down assays were performed as previously
described [29]. HEK293 cells were seeded in 10 cm
2 dishes, the
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After 24 hrs, cellular extracts were prepared using E1A buffer.
The different samples were equalized for the protein concentration
and volume, then incubated with GST fusion proteins immobi-
lized on glutathione agarose for approximately 3–4 hrs at 4uCo n
a rotating wheel. After extensive washing, the bound proteins were
detected using SDS-PAGE and Western blotting.
Rho GTPase activation assays
The amount of activated, GTP-bound Rho proteins was
measured as described previously [45]. Briefly, pull-down assays
were done using purified GST-ELMO (GST fusion protein
containing the full-length RhoG effector, ELMO) with cell
extracts from HEK293 cells transfected with vector control, Dlg
and SGEF either alone or in combination. Similar pull-down
assays were performed with HeLa cells transfected with relevant
siRNAs. Cellular extracts were prepared from HEK293 cells and
HeLa cells after 24 h or 72 h respectively by lysing the cells in
250 ml of 50 mM Tris, pH 7.4, 10 mM MgCl2, 500 mM NaCl,
1% Triton X-100, 0.1% SDS, 0.5% deoxycholate, and protease
inhibitors and then equalized for protein concentration. Lysates
(700–800 mg) were cleared at 16,0006g for 5 min. Supernatants
were incubated with purified GST-ELMO conjugated to gluta-
thione-Sepharose beads for 20 mins at 4uC. After extensive
washing the bound RhoG was analysed by western blotting and
compared with the total RhoG present within the cell lysate.
Immunofluorescence
HaCaT cells were seeded at low cell density on glass coverslips
and were transfected with relevant plasmid DNA using calcium
phosphate precipitation. 24 hrs post transfection, cells were
washed in PBS and fixed in 3.7% paraformaldehyde in PBS
followed by 5 min in 0.1% Triton-PBS. The cells were then
stained with anti-HA monoclonal antibody (Roche) or anti-Flag
monoclonal antibody (Sigma) for 2 h at 37uC, washed extensively
in PBS, and incubated for 20 min at 37uC with a secondary anti-
rabbit or anti-mouse antibody conjugated to fluorescein or
rhodamine (Molecular Probes). Samples were washed several
times with PBS and were mounted with Vectashield mounting
medium (Vector Laboratories) on glass slides and visualized using
a Zeiss LSM 510 confocal microscope.
siRNA experiments
For transient siRNA experiments, cells were seeded in 6-cm
2
dishes and transfected using Lipofectamine 2000 (Invitrogen) with
the following siRNAs from Dharmacon: siRNA against luciferase
as a control, siRNA against HPV-18 E6/E7 (CAUUUAC-
CAGCCCGACGAG), siRNA against HPV-18 E6 (CUAA-
CUAACACUGGGUUAU), siRNA against HPV-16 E6/E7
(UUAAAUGACAGCUCAGAGG), siRNA against hDlg and
siRNA against SGEF.
Subcellular fractionation assays
HEK293 cells were transfected with the relevant plasmids. After
24 hrs, differential extraction of HEK293 cells was performed to
obtain cytoplasmic, membrane, nuclear and cytoskeletal fractions
using the ProteoExtract Fractionation Kit (Calbiochem) according
to the manufacturer’s instructions.
Co-immunoprecipitations
Cells were seeded in 10-cm
2 dishes. After 24 hrs, cell extracts
were prepared in E1A buffer containing protease inhibitor. The
extracts were then passed through a 26G needle multiple times
and then cleared by centrifugation. An equal concentration of
protein from the cellular extracts was incubated with either the
SGEF antibody or the control antibody for approximately 3–4 hrs
on a rotating wheel at 4uC. Protein-A-Sepharose beads (GE
Healthcare) were then added for an additional 50 minutes at 4uC.
The beads were washed three times with extraction buffer
containing protease inhibitor and precipitated proteins were
analysed by Western blot.
Matrigel invasion assays
The matrigel invasion assay was performed using BD Matrigel
Invasion chambers (BD BioCoat) as per the company’s instruc-
tions. In brief, 1.5610
5 cells were seeded in 6-cm
2 dishes and the
next day were transfected using Lipofectamine 2000 (Invitrogen)
with relevant siRNA. After 72 hrs, cells were trypsinised and
counted. Equal numbers of cells were seeded in serum free
medium into the wells and medium containing 20% serum was
added to the lower chambers as a chemo attractant. After 20 hrs,
the cells that had invaded through the matrigel and were on the
lower surface of the chamber were stained using crystal violet. The
entire number of cells that migrated in each assay (performed in
duplicate) were then counted.
Supporting Information
Figure S1 Dlg recruits SGEF to the cytoplasmic cyto-
skeletal network. HaCaT cells transfected with HA-Dlg, Flag-
SGEF or co-transfected with the two cDNAs were fixed and
processed for immunofluorescence with anti-Flag to detect SGEF
and anti-HA to detect Dlg. The upper six panels show typical
staining patterns for SGEF and Dlg when transfected alone. The
lower nine panels show the distribution patterns when Dlg and
SGEF are co-transfected.
(TIF)
Figure S2 HPV-16 E6/E7 are required for maintaining
SGEF expression in CaSki cells. HPV-16 containing CaSki
cells were transfected with control siRNA (luc) or siRNA to 16E6/
E7 and analysed for the levels of SGEF and p53 expression in the
NP-40 soluble and insoluble fractions of the cell after 72 hrs. a-
Actinin was used as a loading control.
(TIF)
Figure S3 HPV-18E6, hDlg and SGEF exist in a complex.
HeLa cells were seeded in 10 cm
2 dishes. After 24 hrs, cellular
extracts were prepared from these cells and immunoprecipitated
using either the control antibody or the anti-hDlg-1 antibody.
SGEF and HPV18-E6 bound to the Dlg were detected using the
anti-SGEF and anti-E6 antibodies respectively. The immunopre-
cipitated Dlg was detected using anti-hDlg-1 antibody. The
bottom 3 lanes show the input levels for hDlg, HPV18-E6 and
SGEF used in this assay.
(TIF)
Figure S4 HPV-18E6 can influence the pattern of SGEF
expression. HaCaT cells were transfected with Flag-tagged
SGEF and HA-tagged HPV-18E6, either alone or in combination.
After 24 hrs the cells were fixed and processed for immunofluo-
rescence with anti-Flag and anti-HA antibodies. The upper two
panels show the pattern of expression of SGEF and E6 alone,
whilst the lower panels shows the patterns of SGEF expression in
two cells with high and low levels of E6 expression.
(TIFF)
Figure S5 Invasive potential of H1299 cells is dependent
upon hDlg and SGEF. H1299 cells were transfected with
hDlg Regulation of SGEF
PLoS Pathogens | www.plospathogens.org 13 February 2012 | Volume 8 | Issue 2 | e1002543siRNAs to Luciferase (Luc), hDlg or SGEF and after 72 hrs the
cells were harvested and equal numbers plated onto Matrigel
invasion chambers. After overnight incubation the numbers of
invading cells in the lower chamber were counted. The graph
shows the fold change in the numbers of invading cells from
multiple assays, where siLuc- transfected cells were scored as the
reference point. Error bars represent 6SD of multiple experi-
ments. The lower panel shows the western blot analysis of the
levels of expression in total cell extracts of hDlg and SGEF
following siRNA transfections performed in parallel with the
invasion assays. a-Actinin is shown as the loading control.
(TIF)
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